Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Déborah Bauer et al.|New England Journal of Medicine|2023Cited by 452
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P. Bhatt, Lacey B. Robinson, Klaus F. Rabe et al.|New England Journal of Medicine|2024Cited by 240
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Evan S. Dellon et al.|New England Journal of Medicine|2024Cited by 107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 100